KR20240055097A - 니르세비맙을 사용한 호흡기 세포융합 바이러스 하기도 감염의 예방 - Google Patents

니르세비맙을 사용한 호흡기 세포융합 바이러스 하기도 감염의 예방 Download PDF

Info

Publication number
KR20240055097A
KR20240055097A KR1020247011813A KR20247011813A KR20240055097A KR 20240055097 A KR20240055097 A KR 20240055097A KR 1020247011813 A KR1020247011813 A KR 1020247011813A KR 20247011813 A KR20247011813 A KR 20247011813A KR 20240055097 A KR20240055097 A KR 20240055097A
Authority
KR
South Korea
Prior art keywords
rsv
nirsevimab
subject
dose
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247011813A
Other languages
English (en)
Korean (ko)
Inventor
토냐 루아나 빌라파나
아만다 리치
마크 토마스 에써
디어드리 일레인 윌킨스
울리카 벨비 함렌
Original Assignee
메디뮨 리미티드
사노피 파스퇴르 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드, 사노피 파스퇴르 인크 filed Critical 메디뮨 리미티드
Publication of KR20240055097A publication Critical patent/KR20240055097A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C07K16/1027—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
KR1020247011813A 2021-09-13 2022-09-12 니르세비맙을 사용한 호흡기 세포융합 바이러스 하기도 감염의 예방 Pending KR20240055097A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163261117P 2021-09-13 2021-09-13
US63/261,117 2021-09-13
US202263266594P 2022-01-10 2022-01-10
US63/266,594 2022-01-10
US202263363633P 2022-04-26 2022-04-26
US63/363,633 2022-04-26
US202263364554P 2022-05-11 2022-05-11
US63/364,554 2022-05-11
PCT/US2022/076311 WO2023039584A2 (en) 2021-09-13 2022-09-12 Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab

Publications (1)

Publication Number Publication Date
KR20240055097A true KR20240055097A (ko) 2024-04-26

Family

ID=83508746

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247011813A Pending KR20240055097A (ko) 2021-09-13 2022-09-12 니르세비맙을 사용한 호흡기 세포융합 바이러스 하기도 감염의 예방

Country Status (9)

Country Link
US (1) US20250340622A1 (cg-RX-API-DMAC7.html)
EP (1) EP4402166A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024535009A (cg-RX-API-DMAC7.html)
KR (1) KR20240055097A (cg-RX-API-DMAC7.html)
AU (1) AU2022341188A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229901A1 (cg-RX-API-DMAC7.html)
IL (1) IL310974A (cg-RX-API-DMAC7.html)
TW (1) TW202340237A (cg-RX-API-DMAC7.html)
WO (1) WO2023039584A2 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60387B1 (sr) 2014-01-15 2020-07-31 Medimmune Llc Rsv-specifična antitela i njihovi funkcionalni delovi
US12024553B2 (en) * 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies

Also Published As

Publication number Publication date
WO2023039584A2 (en) 2023-03-16
WO2023039584A3 (en) 2023-04-06
CA3229901A1 (en) 2023-03-16
IL310974A (en) 2024-04-01
US20250340622A1 (en) 2025-11-06
AU2022341188A1 (en) 2024-03-14
EP4402166A2 (en) 2024-07-24
JP2024535009A (ja) 2024-09-26
TW202340237A (zh) 2023-10-16

Similar Documents

Publication Publication Date Title
Rodriguez-Fernandez et al. Monoclonal antibodies for prevention of respiratory syncytial virus infection
JP7851613B2 (ja) 抗SARS-CoV-2スパイク糖タンパク質抗体を用いてSARS-CoV-2感染及びCOVID-19を治療又は予防するための方法
Fenton et al. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection
US12565526B2 (en) Formulations of anti-RSV antibodies and methods of use thereof
SG11202111748TA (en) Dosage regimens for and compositions including anti-rsv antibodies
EUA Fact sheet for healthcare providers: emergency use authorization for evusheld™(tixagevimab co-packaged with cilgavimab)
Welliver Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection
WO2021260692A1 (en) Compositions and methods for treating infectious disease caused by coronavirus
US20250340622A1 (en) Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab
EA053309B1 (ru) Предупреждение инфекции нижнего респираторного тракта, вызываемой респираторно-синцитиальным вирусом, с помощью нирсевимаба
CN118302441A (zh) 尼塞韦单抗预防呼吸道合胞病毒下呼吸道感染
RU2807524C2 (ru) Составы антител к rsv и способы их применения
CA3115708C (en) Formulations of anti-rsv antibodies and methods of use thereof
KR102703936B1 (ko) 과도한 유리형 light를 포함하는 방법 및 치료
WO2023081434A2 (en) Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
WO2026080293A1 (en) Anti-human rsv f protein antibodies for use in treatment or prophylaxis
KR20220010456A (ko) 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법
KR20220010411A (ko) 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법
CN120513100A (zh) 一种tslp抗体治疗哮喘的方法
KR20220010410A (ko) 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법
CN120000779A (zh) 抗il-5抗体治疗与嗜酸性粒细胞升高相关疾病的用途
WO2021005232A1 (en) Intranasal administration of neutralising antiviral antibodies
KR20220010402A (ko) 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법
Kneyber et al. Respiratory Syncytial Virus (RSV) in the Pediatric Intensive Care Unit
Fernández et al. Research article A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)